Extracellular signal-regulated kinase inhibition prevents venous adaptive remodeling via regulation of Eph-B4

Abstract

Objectives

Vein graft adaptation (VGA) is a process that vein as a vascular graft conduits in arterial reconstructive surgery; VGA can lead to postoperative vein graft stenosis (VGS) and complications after coronary artery bypass graft and other peripheral artery bypass surgeries. VGA is characterized by vein graft loss the venous features without exhibiting arterial features; furthermore, the activation of ERK inhibited the maintenance of venous properties of the vein graft. We hypothesized that ERK inhibition can affect vein VGS through regulating the expression of EphB4.

Methods

Rat vein transplantation model was established using wild-type and EphB4^+/− Sprague-Dawley rats. Hematoxylin-eosin, Masson, Verhoeff, actin staining, and immunohistochemistry were applied to observe the structure of the vein grafts. Vascular smooth muscle cells (VSMCs) were isolated from the vein and vein grafts. Western blotting was used to determine the expression of p-ERK1/2 and EphB4, and immunofluorescence was applied to detect the expression and location of EphB4. Cell wound scratch assay and CCK8 assay were used to determine the migration and proliferation of VSMCs. Real-time polymerase chain reaction was used to determine the mRNA expression of EphB4.

Results

Western blotting in vein sample and vein graft sample detected p-ERK1/2 and ERK1/2 expression in both EphB4^+/+ and EphB4^+/− rats. The expression of p-ERK was increased in vein graft compared to vein. Immunofluorescence in VSMCs form EphB4^+/+ and EphB4^+/− rats detected EphB4 expression in both cells, and the expression of EphB4 was increased in VSMCs form EphB4^+/+ rats. SCH772984 reduces the proliferation and migration of VSMCs. Inhibition of ERK suppressed the increase of vein graft wall thickness, and the expression of collagen fibers, elastic fibers, and α-actin was decreased. Vein graft from EphB4^+/− rats reduces the expression of EphB4, and SCH772984 suppressed the decrease of EphB4 in vivo. Vein graft from EphB4^+/− rats increased the expression of EphB4, and SCH772984 suppressed the increase of EphB4 in vivo.

Conclusions

The inhibition of ERK1/2 suppressed the process of VGS by decreasing the proliferation of VSMCs. The ERK-inhibitor SCH772984 suppressed the level of VGS by extending the time of EphB4 expression during the process of VGA, thus maintaining the venousization of vein graft. The mechanism may be that the inhibitor SCH772984 suppresses the level of VGS by extending the time of EphB4 expression during the process of VGA. Therefore, our research provides a new target of VGS treatment by inhibiting the expression of ERK1/2 through the process of VGA.

Keywords

Vein graft stenosis vein graft adaptation ERK1/2 EphB4 VSMCs transgenic rats

Get full access to this article

View all access options for this article.

References

Campeau

Hunninghake

Knatterud

, et al. Aggressive cholesterol lowering delays saphenous vein graft atherosclerosis in women, the elderly, and patients with associated risk factors. NHLBI post coronary artery bypass graft clinical trial. Post CABG Trial Investigators 1999; 99: 3241.

Hoye

Lemos

Arampatzis

, et al. J Invasive Cardiol 2004; 16: 230–233.

Christiansen

JFH

Bechtel

JFM.

Diseased vein grafts express elevated inflammatory cytokine levels compared with atherosclerotic coronary arteries. Ann Thorac Surg 2004; 77: 1579.

Feigel

Muto

Fancher

, et al. A novel cellular model of vein graft adaptation. J Vasc Surg 51: 533.

Davies

Magee

Hayward

, et al. Prediction of long saphenous vein graft adaptation. Eur J Vasc Surg 8(4): 478–481.

Davies

Hagen

P-O.

Vein graft adaptation in the arterial circulation. J Vasc Intervent Radiol 1997; 8: 697–699.

Mitra

AKG

Agrawal

DK.

Cellular, molecular and immunological mechanisms in the pathophysiology of vein graft intimal hyperplasia. Immunol Cell Biol 2006; 84: 115–124.

Chu

Rha

S-W

Kuchulakanti

, et al. Efficacy of Sirolimus-Eluting stents compared with bare metal stents for saphenous vein graft intervention. Am J Cardiol 2006; 97: 34–37.

Muto

Model

Ziegler

, et al. Mechanisms of vein graft adaptation to the arterial circulation. Circ J 2010; 74: 1501–1512.

10.

Somers

Knaapen

The histopathology of varicose vein disease. Angiology 2006; 57: 546–555.

11.

Airik

Trowe

M-O

Foik

, et al. Hydroureternephrosis due to loss of Sox9-regulated smooth muscle cell differentiation of the ureteric mesenchyme. Hum Mol Genet 2010; 19: 4918–4929.

12.

Veith

Gupta

Ascer

, et al. Six-year prospective multicenter randomized comparison of autologous saphenous vein and expanded polytetrafluoroethylene grafts in infrainguinal arterial reconstructions. J Vasc Surg 1986; 3: 104–114.

13.

Fitzgibbon

Kafka

Leach

, et al. Coronary bypass graft fate and patient outcome: angiographic follow-up of 5,065 grafts related to survival and reoperation in 1,388 patients during 25 years. J Am Coll Cardiod 1996; 28: 616–626.

14.

Wang

Wenfeng

Wang

Effect of antisense c-myc oligodeoxynucleotides on intimal hyperplasia of vein autografts of rats. Chin J Exp Surg 2000 17(3): 324–325.

15.

Newby

Zaltsman

AB.

Molecular mechanisms in intimal hyperplasia. J Pathol 2000; 190: 300–309.

16.

Kawabata

Shiroma

Koja

, et al. Pathophysiological features of intimal hyperplasia of the arterially implanted autovein graft and its anastomosis in dogs. Int J Angiol 1998; 7: 150–156.

17.

Conte

Bandyk

Clowes

, et al. Results of PREVENT III: a multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery. J Vasc Surg 2006; 43: 742–751.

18.

Investigators

PI.

Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery, prevent IV: a randomized control trial. J Am Med Assoc 2006; 294: 427.

19.

Murphy

Johnson

Chamberlain

, et al. Short- and long-term effects of cytochalasin D, paclitaxel and rapamycin on wall thickening in experimental porcine vein grafts. Cardiovasc Res 2007; 73: 607–617.

20.

Chen

Liu

Meng

, et al. Local application of rapamycin inhibits vein graft restenosis in rabbits. Transp Proc 2011; 43: 2017–2021.

21.

Rajathurai

Rizvi

Lin

, et al. Periadventitial rapamycin-eluting microbeads promote vein graft disease in long-term pig vein-into-artery interposition grafts. Circ Cardiovasc Interv 2010; 3: 157–165.

22.

Ehsan

Mann

Dell’Acqua

, et al. Long-term stabilization of vein graft wall architecture and prolonged resistance to experimental atherosclerosis after E2F decoy oligonucleotide gene therapy. J Thorac Cardiovasc Surg 2001; 121: 714–722.

23.

Mann

Whittemore

Donaldson

, et al. Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial. Lancet 1999; 354: 1493–1498.

24.

Roy-Chaudhury

Arend

Zhang

, et al. Neointimal hyperplasia in early arteriovenous fistula failure. Am J Kidney Dis 2007; 50: 782–790.

25.

Mehta

Mukherjee

Patterson

, et al. Pathology of explanted polytetrafluoroethylene vascular grafts. Cardiovasc Pathol 2011; 20: 0–221.

26.

Schanzer

Hevelone

Owens

, et al. Technical factors affecting autogenous vein graft failure: observations from a large multicenter trial. J Vasc Surg 2007; 46: 1180–1190.

27.

McCabe

Cunningham

Wyatt

, et al. A histological and histochemical examination of autogenous vein grafts. 1967.

28.

Korff

Endothelial EphrinB2 is controlled by microenvironmental determinants and associates context-dependently with CD31. Atvb 2005; 26(3): 468–474.

29.

Gale

NWB

Pan

, et al. Ephrin-B2 selectively marks arterial vessels and neovascularization sites in the adult, with expression in both endothelial and smooth-muscle cells. Dev Biol 2001; 230: 160.

30.

Shin

Garcia-Cardena

Hayashi

S-I

, et al. Expression of EphrinB2 identifies a stable genetic difference between arterial and venous vascular smooth muscle as well as endothelial cells, and marks subsets of microvessels at sites of adult neovascularization. Dev Biol 2001; 230: 0–150.

31.

Hong

McCullough

Stegemann

JP.

The role of ERK signaling in protein hydrogel remodeling by vascular smooth muscle cells. Biomaterials 2007; 28: 3824–3833.

32.

Shao

Guan

Wang

, et al. CRISPR/Cas-mediated genome editing in the rat via direct injection of one-cell embryos. Nat Protoc 2014; 9: 2493–2512.

33.

Garbey

Berceli

SA.

A dynamical system that describes vein graft adaptation and failure. J Theor Biol 2013; 336: 209–220. (Complete):

34.

Chakravarty

Morrissey

Wertman

, et al. Comparison of long-term outcomes of drug-eluting stents and bare metal stents for saphenous vein graft stenosis. Catheter Cardiovasc Interv 2012; 79: 903–909.

35.

Huang

, et al. Popranolol inhibits the VEGF inducing ERK expression in human umbilical vein endothelial cells. J Clin Dermatol 2012; 41: 587–589.

36.

Muto

Harrison

, et al. Eph-B4 prevents venous adaptive remodeling in the adult arterial environment. J Exp Med 2011; 208: 561–575.

37.

Das

Shergill

Thakur

, et al. Ephrin B2/EphB4 pathway in hepatic stellate cells stimulates Erk-dependent VEGF production and sinusoidal endothelial cell recruitment. Am J Physiol Gastrointest Liver Physiol 2010; 298(6): G908–G915.

38.

Garrett

Dennis

DeBakey

ME.

Aortocoronary bypass with saphenous vein graft. Seven-year follow-up. 1973. J Am Med Assoc 1996; 276: 15179–15120.

39.

Yusuf

Zucker

Peduzzi

, et al. Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the coronary artery bypass graft surgery trialists collaboration. Lancet 1994; 344: 563–570.

40.

Wang

Collins

Foster

, et al. Eph-B4 mediates vein graft adaptation by regulation of endothelial nitric oxide synthase. J Vasc Surg 2017; 65: 179–189.

41.

Jadlowiec

Feigel

Yang

, et al. Reduced adult endothelial cell EphB4 function promotes venous remodeling. Am J Physiol Cell Physiol 2013; 304: C627–C635.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.93 MB

0.30 MB